Literature DB >> 30285209

Clostridioides difficile Infection.

Alice Y Guh1, Preeta K Kutty1.   

Abstract

Clostridioides difficile (formerly Clostridium difficile) infection is the most frequently identified health care-associated infection in the United States. C difficile has also emerged as a cause of community-associated diarrhea, resulting in increased incidence of community-associated infection. Clinical illness ranges in severity from mild diarrhea to fulminant colitis and death. Appropriate management of infection requires understanding of the various diagnostic assays and therapeutic options as well as relevant measures to infection prevention. This article provides updated recommendations regarding the prevention, diagnosis, and treatment of incident and recurrent C difficile infection.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30285209      PMCID: PMC6524133          DOI: 10.7326/AITC201810020

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  63 in total

1.  Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection.

Authors:  G Cammarota; L Masucci; G Ianiro; S Bibbò; G Dinoi; G Costamagna; M Sanguinetti; A Gasbarrini
Journal:  Aliment Pharmacol Ther       Date:  2015-03-01       Impact factor: 8.171

2.  Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients.

Authors:  L V McFarland; C M Surawicz; W E Stamm
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

3.  Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea.

Authors:  Lorraine Kyne; Stavros Sougioultzis; Lynne V McFarland; Ciarán P Kelly
Journal:  Infect Control Hosp Epidemiol       Date:  2002-11       Impact factor: 3.254

4.  Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube.

Authors:  Johannes Aas; Charles E Gessert; Johan S Bakken
Journal:  Clin Infect Dis       Date:  2003-02-14       Impact factor: 9.079

5.  Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.

Authors:  Oliver A Cornely; Derrick W Crook; Roberto Esposito; André Poirier; Michael S Somero; Karl Weiss; Pamela Sears; Sherwood Gorbach
Journal:  Lancet Infect Dis       Date:  2012-02-08       Impact factor: 25.071

6.  Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy.

Authors:  S S Johal; J Hammond; K Solomon; P D James; Y R Mahida
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

7.  A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.

Authors:  Fred A Zar; Srinivasa R Bakkanagari; K M L S T Moorthi; Melinda B Davis
Journal:  Clin Infect Dis       Date:  2007-06-19       Impact factor: 9.079

8.  A case-control study of community-associated Clostridium difficile infection.

Authors:  M H Wilcox; L Mooney; R Bendall; C D Settle; W N Fawley
Journal:  J Antimicrob Chemother       Date:  2008-04-22       Impact factor: 5.790

Review 9.  Current status of Clostridium difficile infection epidemiology.

Authors:  Fernanda C Lessa; Carolyn V Gould; L Clifford McDonald
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

10.  Effects of control interventions on Clostridium difficile infection in England: an observational study.

Authors:  Kate E Dingle; Xavier Didelot; T Phuong Quan; David W Eyre; Nicole Stoesser; Tanya Golubchik; Rosalind M Harding; Daniel J Wilson; David Griffiths; Alison Vaughan; John M Finney; David H Wyllie; Sarah J Oakley; Warren N Fawley; Jane Freeman; Kirsti Morris; Jessica Martin; Philip Howard; Sherwood Gorbach; Ellie J C Goldstein; Diane M Citron; Susan Hopkins; Russell Hope; Alan P Johnson; Mark H Wilcox; Timothy E A Peto; A Sarah Walker; Derrick W Crook
Journal:  Lancet Infect Dis       Date:  2017-01-25       Impact factor: 71.421

View more
  24 in total

1.  Identification of ADS024, a newly characterized strain of Bacillus velezensis with direct Clostridiodes difficile killing and toxin degradation bio-activities.

Authors:  Michelle M O'Donnell; James W Hegarty; Brian Healy; Sarah Schulz; Calum J Walsh; Colin Hill; R Paul Ross; Mary C Rea; Ronald Farquhar; Laurent Chesnel
Journal:  Sci Rep       Date:  2022-06-03       Impact factor: 4.996

2.  Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection.

Authors:  Shaohui Wang; Duolong Zhu; Xingmin Sun
Journal:  Microbiol Spectr       Date:  2022-05-18

3.  High Dose Intramuscular Vitamin D3 Supplementation Impacts the Gut Microbiota of Patients With Clostridioides Difficile Infection.

Authors:  Sang Hoon Lee; Han-Ki Park; Chang Don Kang; Dae Hee Choi; Sung Chul Park; Jin Myung Park; Seung-Joo Nam; Gi Bong Chae; Kyoung Yul Lee; Hyunseok Cho; Sung Joon Lee
Journal:  Front Cell Infect Microbiol       Date:  2022-06-06       Impact factor: 6.073

4.  Clostridioides difficile specific DNA adenine methyltransferase CamA squeezes and flips adenine out of DNA helix.

Authors:  Jujun Zhou; John R Horton; Robert M Blumenthal; Xing Zhang; Xiaodong Cheng
Journal:  Nat Commun       Date:  2021-06-08       Impact factor: 14.919

5.  Gut microbiota composition in health-care facility-and community-onset diarrheic patients with Clostridioides difficile infection.

Authors:  Giovanny Herrera; Laura Vega; Manuel Alfonso Patarroyo; Juan David Ramírez; Marina Muñoz
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

6.  Identification of linear epitopes on the flagellar proteins of Clostridioides difficile.

Authors:  A Razim; K Pacyga; P Naporowski; D Martynowski; A Szuba; A Gamian; S Górska
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

7.  Clostridium difficile Infection Hospitalizations in the United States: Insights From the 2017 National Inpatient Sample.

Authors:  Dhanshree Solanki; Asim Kichloo; Zain El-Amir; Dushyant Singh Dahiya; Jagmeet Singh; Farah Wani; Shantanu Solanki
Journal:  Gastroenterology Res       Date:  2021-04-21

8.  Inhibition of the Clostridioides difficile Class D β-Lactamase CDD-1 by Avibactam.

Authors:  Nichole K Stewart; Marta Toth; Anastasiya Stasyuk; Mijoon Lee; Clyde A Smith; Sergei B Vakulenko
Journal:  ACS Infect Dis       Date:  2021-01-03       Impact factor: 5.084

9.  Integrated Metagenomic and Transcriptomic Analyses Reveal the Dietary Dependent Recovery of Host Metabolism From Antibiotic Exposure.

Authors:  Bingbing Li; Huihui Qiu; Ningning Zheng; Gaosong Wu; Yu Gu; Jing Zhong; Ying Hong; Junli Ma; Wen Zhou; Lili Sheng; Houkai Li
Journal:  Front Cell Dev Biol       Date:  2021-06-18

Review 10.  Lights and Shadows of Microbiota Modulation and Cardiovascular Risk in HIV Patients.

Authors:  Pablo Villoslada-Blanco; Patricia Pérez-Matute; José A Oteo
Journal:  Int J Environ Res Public Health       Date:  2021-06-25       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.